This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Baidu(BIDU - Get Report) rated new Buy at Jefferies. $200 price target. Company is a market leader with limited competition.
Comerica(CMA - Get Report) rated new Market Perform at Morgan Keegan. $38 price target. Visibility remains low for potential loan growth.
Fastenal(FAST - Get Report) upgraded at UBS from Neutral to Buy. $72 price target. Estimates also boosted, as sales growth can drive margin expansion.
Henry Schein(HSIC) upgraded at Goldman to Buy, Goldman Sachs said. $80 price target. Industry should benefit from improving macro trends.
Intermune(ITMN) upgraded to Outperform at Wells Fargo. Expecting a more robust Esbriet launch.
Perrigo(PRGO) upgraded at from Sell to Neutral, Goldman Sachs said. $80 price target. Company can move past the FDA issue and should continue to realize synergies from recent deals.
Riverbed Technology(RVBD) upgraded at ThinkEquity from Hold to Buy. $48 price target. Guidance confirms recent checks that show demand can recover.
Riverbed Technology(RVBD) upgraded at Oppenheimer from Perform to Outperform, Oppenheimer said. $40 price target. Company pre-announced to the upside, easing some demand concerns.
Sirona Dental(SIRO) rated new Buy at Goldman. Company was also addded to the Conviction Buy list. Company is leverage to increased spending on high-tech equipment. $61 price target.
Sunoco(SUN - Get Report) downgraded at Benchmark from Hold to Sell, Benchmark Company said. $34 price target. Company is facing an unfavorable settlement for coke pricing.
Dentsply(XRAY - Get Report) rated new Neutral at Goldman Sachs. $39 price target. Stock is already pricing in improving industry growth.
End of report.